{"entity":{"id":"crossignal-therapeutics","kind":"company","name":"Crossignal Therapeutics","aka":[],"tldr":"Crossignal Therapeutics develops small-molecule medicines meant to stop tumours hiding from the immune system. Its lead drug, CT3001, is in an early trial in advanced bowel, pancreatic and other solid cancers.","summary":"Crossignal Therapeutics, Inc., of La Jolla, California, develops small-molecule anti-cancer immunotherapies, using an assay platform it calls PPS to screen against difficult G-protein-coupled receptor targets. Its lead, CT3001, is described as a first-in-class small-molecule inhibitor of GPR35; company news links it to IDO1-mediated tumour immune escape through the Hippo-YAP pathway. CT3001 received FDA IND clearance in December 2023 and the company announced first-in-patient dosing in October 2024 in a phase 1/2 study (NCT06598007) of CT3001 alone and with FOLFOX, with a phase 2a part planned in advanced colorectal or pancreatic cancer. A second programme, CT3021, is a small-molecule antagonist of adenosine A2a, A2b and A1 receptors. Its first registered cancer trial, NCT06598007, was posted on ClinicalTrials.gov in September 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://crossignaltherapeutics.com/"},{"label":"CT3001 clinical trial page","url":"https://crossignaltherapeutics.com/clinical-trial"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic","gastric","nsclc"],"sections":["immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06598007"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[" No OnCo technology record matches a small-molecule GPR35 inhibitor, so none is linked; CT3001 is not an antibody against PD-1, PD-L1 or CTLA-4.","Founding year and financing not stated on the company website.","Company website, news and clinical trial pages read on 29 October 2026."],"hq":"La Jolla, CA","country":"US","companyType":"biotech","website":"https://crossignaltherapeutics.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/crossignal-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"trial":[{"id":"nct06598007","kind":"trial","name":"A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors","route":"/trials/nct06598007/"}]}}